The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

This trial is studying the combination of anlotinib (a drug that blocks tumor blood vessel growth) and fulvestrant (a hormone therapy) in women with hormone receptor-positive, HER2-negative advanced breast cancer. **You may be eligible if...** - You are a woman aged 18 or older - You have HR-positive, HER2-negative breast cancer that is advanced or metastatic - Your cancer relapsed within 12 months of at least 2 years of hormone therapy, or progressed after at least 6 months of hormone salvage therapy - You have not received more than one prior chemotherapy regimen for metastatic disease - You have at least one measurable tumor - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have previously received fulvestrant or anti-angiogenic drugs - Your cancer involves a life-threatening organ crisis (visceral crisis) - You have uncontrolled brain metastases - You are pregnant or breastfeeding - You have uncontrolled high blood pressure or significant clotting/bleeding problems Talk to your doctor to see if this trial is right for you.